José Mejía Oneto, Shasqi CEO

A bet­ter way to con­trol where drugs go? In­vestors bet on small biotech's mis­sion to 'click' to­geth­er can­cer meds

While José Mejía One­to was an or­tho­pe­dic surgery res­i­dent at UC Davis, he learned an in­trigu­ing yet frus­trat­ing fact: On­ly small amounts of a drug — in some cas­es just 1% or 2% of what’s ad­min­is­tered — ac­tu­al­ly make it to the tar­get lo­ca­tion.

That con­cern­ing fact left Mejía One­to with one ques­tion, one that would change the tra­jec­to­ry of his en­tire ca­reer — how can we bet­ter con­trol where drugs go?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.